Nifty
:
22795.90
Sensex
:
75311.06
-117.25 (-0.51%)
-424.90 (-0.56%)
Nifty
Sensex
:
:
22795.90
75311.06
-117.25 (-0.51%)
-424.90 (-0.56%)

Strides Pharma Science Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 532531 | NSE: STAR

NSE BSE
729.20
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  739.85
  •  760.95
  •  721.50
  •  738.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1107046
  •  8170.85
  •  760.95
  •  300.81

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 6,018.69
  • 22.33
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 8,058.55
  • 0.38%
  • 2.55

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.82%
  • 2.82%
  • 20.87%
  • FII
  • DII
  • Others
  • 28.48%
  • 15.17%
  • 5.84%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.98
  • 6.33
  • 9.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.35
  • 7.52
  • 26.41

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -18.90
  • -11.45
  • -35.27

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.53
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.23
  • 2.34
  • 2.49

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.25
  • 16.24
  • 17.60

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
-7.76
44.3
63.65
80.19
P/E Ratio
34.51
24.02
19.07
Revenue
4051
4657
5165
5816
EBITDA
743
947
1104
1283
Net Income
-71
410
572
720
ROA
-1.1
7.3
9
10.5
P/Bk Ratio
6.61
5.61
4.62
3.76
ROE
-3.26
15.6
19.47
20.17
FCFF
307.79
695.25
867.05
938.95
FCFF Yield
2.02
4.56
5.68
6.15

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
1,153.67
1,005.77
14.71%
1,201.11
999.43
20.18%
1,087.50
929.99
16.94%
1,084.04
986.37
9.90%
Expenses
943.35
863.78
9.21%
965.30
846.30
14.06%
870.52
763.40
14.03%
854.30
830.81
2.83%
EBITDA
210.31
141.99
48.12%
235.81
153.13
53.99%
216.98
166.59
30.25%
229.73
155.56
47.68%
EBIDTM
18.23%
14.12%
19.63%
15.32%
19.95%
17.91%
21.19%
15.77%
Other Income
5.62
8.75
-35.77%
28.41
35.85
-20.75%
12.72
8.64
47.22%
-13.55
27.12
-
Interest
52.18
69.71
-25.15%
82.15
78.59
4.53%
80.39
76.42
5.19%
80.16
80.52
-0.45%
Depreciation
48.42
49.44
-2.06%
50.52
60.10
-15.94%
48.59
59.59
-18.46%
49.76
60.93
-18.33%
PBT
112.89
21.52
424.58%
127.67
-114.64
-
96.98
33.25
191.67%
78.20
33.89
130.75%
Tax
23.80
15.74
51.21%
21.20
-7.44
-
16.86
9.68
74.17%
19.25
7.09
171.51%
PAT
89.09
5.78
1,441.35%
106.47
-107.20
-
80.12
23.57
239.92%
58.95
26.81
119.88%
PATM
7.72%
0.57%
8.86%
-10.73%
7.37%
2.53%
5.44%
2.72%
EPS
9.54
5.41
76.34%
10.14
-14.54
-
7.64
-0.77
-
1.98
-1.06
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
4,526.32
4,051.12
3,688.39
3,070.25
3,315.87
2,981.12
3,108.33
3,344.37
3,826.22
2,862.19
1,195.85
Net Sales Growth
15.42%
9.83%
20.13%
-7.41%
11.23%
-4.09%
-7.06%
-12.59%
33.68%
139.34%
 
Cost Of Goods Sold
1,814.72
1,640.50
1,626.88
1,502.32
1,332.79
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
560.49
Gross Profit
2,711.60
2,410.62
2,061.50
1,567.93
1,983.08
1,858.64
2,023.14
1,965.53
2,545.05
1,359.90
635.37
GP Margin
59.91%
59.51%
55.89%
51.07%
59.81%
62.35%
65.09%
58.77%
66.52%
47.51%
53.13%
Total Expenditure
3,633.47
3,318.01
3,303.09
3,091.76
2,689.06
2,470.90
2,811.65
3,108.66
3,309.30
2,481.62
967.00
Power & Fuel Cost
-
86.47
85.82
71.54
64.58
64.49
54.39
51.33
33.87
77.18
16.02
% Of Sales
-
2.13%
2.33%
2.33%
1.95%
2.16%
1.75%
1.53%
0.89%
2.70%
1.34%
Employee Cost
-
751.13
732.02
646.91
550.15
442.56
329.44
434.05
419.16
357.69
172.06
% Of Sales
-
18.54%
19.85%
21.07%
16.59%
14.85%
10.60%
12.98%
10.95%
12.50%
14.39%
Manufacturing Exp.
-
314.63
259.45
255.52
237.94
210.79
150.98
115.97
137.47
119.23
41.37
% Of Sales
-
7.77%
7.03%
8.32%
7.18%
7.07%
4.86%
3.47%
3.59%
4.17%
3.46%
General & Admin Exp.
-
253.44
232.21
223.67
191.73
191.89
150.10
194.38
172.63
198.71
86.25
% Of Sales
-
6.26%
6.30%
7.29%
5.78%
6.44%
4.83%
5.81%
4.51%
6.94%
7.21%
Selling & Distn. Exp.
-
224.81
263.65
331.30
223.22
137.07
111.22
208.85
161.12
129.57
61.37
% Of Sales
-
5.55%
7.15%
10.79%
6.73%
4.60%
3.58%
6.24%
4.21%
4.53%
5.13%
Miscellaneous Exp.
-
47.02
103.06
60.51
88.65
301.61
930.33
725.25
1,103.88
96.95
61.37
% Of Sales
-
1.16%
2.79%
1.97%
2.67%
10.12%
29.93%
21.69%
28.85%
3.39%
2.46%
EBITDA
892.83
733.11
385.30
-21.51
626.81
510.22
296.68
235.71
516.92
380.57
228.85
EBITDA Margin
19.73%
18.10%
10.45%
-0.70%
18.90%
17.12%
9.54%
7.05%
13.51%
13.30%
19.14%
Other Income
33.20
49.85
135.22
133.40
59.44
66.70
322.90
920.64
398.08
102.37
38.57
Interest
294.88
314.44
261.14
176.74
150.06
155.72
79.29
196.24
183.10
168.17
47.44
Depreciation
197.29
220.68
243.25
233.01
206.29
187.79
171.85
193.93
198.69
131.25
64.03
PBT
415.74
247.84
16.11
-297.88
329.90
233.42
368.44
766.17
533.20
183.50
155.95
Tax
81.11
31.59
-55.30
-178.26
31.65
17.91
14.49
21.41
51.19
42.45
147.60
Tax Rate
19.51%
53.72%
6010.87%
32.91%
8.48%
11.50%
3.71%
2.96%
10.30%
29.87%
99.35%
PAT
334.63
-124.83
-221.20
-460.21
352.32
143.62
370.31
681.31
399.38
113.21
1.57
PAT before Minority Interest
341.73
-148.53
-230.90
-474.25
341.61
137.82
375.57
701.18
445.58
99.68
0.98
Minority Interest
7.10
23.70
9.70
14.04
10.71
5.80
-5.26
-19.87
-46.20
13.53
0.59
PAT Margin
7.39%
-3.08%
-6.00%
-14.99%
10.63%
4.82%
11.91%
20.37%
10.44%
3.96%
0.13%
PAT Growth
755.62%
-
-
-
145.31%
-61.22%
-45.65%
70.59%
252.78%
7,110.83%
 
EPS
36.29
-13.54
-23.99
-49.91
38.21
15.58
40.16
73.89
43.32
12.28
0.17

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
2,125.56
2,212.26
2,359.23
2,776.66
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
1,144.92
Share Capital
91.90
90.30
89.79
89.68
89.56
89.55
89.50
89.42
89.35
59.62
Total Reserves
2,030.57
2,102.54
2,266.99
2,682.26
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
1,084.50
Non-Current Liabilities
621.44
1,210.30
965.72
1,264.45
813.65
2,342.88
2,067.29
2,048.67
2,760.03
285.79
Secured Loans
618.40
1,040.81
744.86
873.43
601.79
1,806.45
1,551.09
1,622.87
2,614.88
250.23
Unsecured Loans
53.10
98.98
90.77
9.15
2.12
0.06
0.23
14.84
12.13
17.16
Long Term Provisions
91.63
73.42
64.28
246.50
63.95
52.24
16.55
25.19
14.45
6.02
Current Liabilities
2,879.26
2,990.20
3,411.68
2,738.35
2,544.86
2,662.24
1,899.30
3,103.87
1,891.98
1,019.94
Trade Payables
851.59
982.34
1,071.52
1,134.20
797.75
888.99
712.07
774.09
775.40
234.41
Other Current Liabilities
341.57
527.89
697.18
421.00
354.49
248.12
129.98
819.08
347.93
502.47
Short Term Borrowings
1,574.15
1,330.76
1,496.53
1,023.84
1,228.78
1,339.02
944.39
1,393.96
700.48
203.03
Short Term Provisions
111.94
149.20
146.43
159.31
163.84
186.11
112.86
116.73
68.19
80.03
Total Liabilities
5,572.40
6,373.38
6,760.72
6,816.80
5,953.17
7,806.77
6,584.90
8,034.86
7,360.09
2,469.36
Net Block
1,853.18
2,298.42
2,333.45
2,151.13
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
701.36
Gross Block
2,873.18
3,324.82
3,231.69
2,841.28
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
1,080.55
Accumulated Depreciation
1,020.00
1,026.40
898.24
690.15
508.53
478.92
326.03
277.09
146.75
379.19
Non Current Assets
2,603.41
3,130.03
3,398.88
3,999.57
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
1,039.91
Capital Work in Progress
161.89
150.98
291.08
447.37
412.95
453.03
620.29
780.18
814.88
171.17
Non Current Investment
196.93
438.96
540.34
666.23
503.24
494.34
350.08
315.66
127.19
68.76
Long Term Loans & Adv.
256.13
217.18
210.58
185.80
210.82
223.69
197.22
222.56
201.83
96.72
Other Non Current Assets
123.38
11.91
10.26
549.04
428.19
16.86
30.72
15.62
22.62
1.91
Current Assets
2,969.00
3,135.25
3,361.83
2,817.23
2,372.11
3,048.72
2,483.59
3,791.82
3,514.89
1,429.44
Current Investments
105.76
50.84
0.00
99.41
118.97
284.75
311.48
1,279.54
1,213.76
561.29
Inventories
1,126.24
1,146.51
1,173.80
1,200.70
782.54
874.16
552.02
732.80
613.14
207.68
Sundry Debtors
1,141.87
1,299.40
1,207.30
1,110.59
931.69
987.18
882.18
995.91
1,032.97
389.96
Cash & Bank
191.17
315.96
187.35
179.76
237.10
516.65
303.33
329.48
311.59
146.88
Other Current Assets
403.96
169.21
647.90
98.22
301.81
385.98
434.59
454.09
343.44
123.64
Short Term Loans & Adv.
174.97
153.34
145.49
128.54
218.24
249.11
295.75
244.39
97.54
54.46
Net Current Assets
89.74
145.05
-49.84
78.89
-172.75
386.48
584.29
687.95
1,622.91
409.50
Total Assets
5,572.41
6,265.28
6,760.71
6,816.80
5,953.16
7,806.77
6,584.90
8,034.87
7,360.09
2,469.35

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
701.07
44.41
-257.81
481.44
204.79
60.05
187.07
288.14
73.25
83.40
PBT
-62.72
-267.63
-652.51
289.38
48.51
344.37
705.80
497.14
146.44
992.01
Adjustment
818.27
682.19
582.27
363.31
527.49
94.59
-274.51
190.92
345.56
-756.73
Changes in Working Capital
-78.73
-457.80
-189.90
-328.05
-326.23
-323.14
-190.66
-341.30
-341.71
-95.91
Cash after chg. in Working capital
676.82
-43.23
-260.14
324.64
249.76
115.82
240.63
346.76
150.29
139.37
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
24.25
87.64
2.33
156.80
-44.98
-55.76
-53.56
-58.62
-77.04
-55.97
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-150.25
302.47
-118.73
-520.82
1,306.16
-148.49
582.59
-686.69
-2,224.83
51.87
Net Fixed Assets
-75.44
-54.00
-61.59
-86.75
-167.06
-48.49
677.20
-236.66
-535.93
-66.57
Net Investments
-6.57
-92.01
62.72
-219.57
-17.15
-383.09
747.64
-143.27
-1,478.58
78.09
Others
-68.24
448.48
-119.86
-214.50
1,490.37
283.09
-842.25
-306.76
-210.32
40.35
Cash from Financing Activity
-693.32
-213.92
421.32
-15.80
-1,709.45
194.27
-1,015.69
338.21
2,943.94
-421.25
Net Cash Inflow / Outflow
-142.51
132.96
44.77
-55.18
-198.50
105.83
-246.03
-60.33
792.35
-285.98
Opening Cash & Equivalents
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.91
586.00
Closing Cash & Equivalent
161.02
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.42

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
230.95
242.83
262.48
309.09
281.55
294.94
274.26
306.41
296.83
191.91
ROA
-2.49%
-3.52%
-6.99%
5.35%
2.00%
5.22%
9.59%
5.79%
2.03%
0.04%
ROE
-6.88%
-10.15%
-18.49%
12.91%
5.34%
14.74%
27.00%
16.53%
5.25%
0.09%
ROCE
4.15%
-0.49%
-9.49%
11.17%
6.01%
8.65%
16.07%
10.75%
7.54%
10.92%
Fixed Asset Turnover
2.02
1.91
1.75
2.04
1.50
1.17
1.04
1.27
1.47
1.21
Receivable days
71.28
73.25
79.41
68.09
70.88
79.95
102.49
96.77
90.73
114.71
Inventory Days
66.36
67.80
81.35
66.13
61.20
61.00
70.11
64.20
52.34
58.37
Payable days
204.02
230.40
267.95
264.54
138.58
146.59
116.23
117.33
75.51
76.81
Cash Conversion Cycle
-66.38
-89.35
-107.20
-130.32
-6.50
-5.64
56.37
43.64
67.55
96.27
Total Debt/Equity
1.14
1.27
1.18
0.76
0.78
1.22
1.03
1.35
1.34
0.78
Interest Cover
0.63
-0.10
-2.69
3.49
2.00
5.92
4.68
3.71
1.85
4.13

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Strides Pharma Scien - Quarterly Results
    30th Jan 2025, 13:21 PM

    Read More
  • Strides Pharma Science’s arm gets USFDA’s approval for Acetaminophen and Ibuprofen Tablets
    20th Jan 2025, 16:42 PM

    The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.